MedTrace Logo

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 695

Last updated 2026-05-05

No results posted yet for this study

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.

Conditions

  • Advanced Solid Malignancies

Interventions

DRUG

AZD9574

Participants will receive AZD9574 orally.

DRUG

Temozolomide (TMZ)

Participants will receive temozolomide orally.

DRUG

[11C]AZ1419 3391

Participants will receive \[11C\]AZ1419 3391 intravenously.

DRUG

Trastuzumab Deruxtecan (T-DXd)

Participants will receive T-DXd intravenously.

DRUG

Datopotamab Deruxtecan (Dato-DXd)

Participants will receive Dato-DXd intravenously.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-24
Primary Completion
2027-10-13
Completion
2027-10-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • South Korea
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05417594 on ClinicalTrials.gov